FY2025 EPS Estimates for Repligen Reduced by Leerink Partnrs

Repligen Corporation (NASDAQ:RGEN) – Stock analysts at Leerink Partnrs decreased their FY2025 EPS estimates for Repligen in a research report issued to clients and investors on Tuesday, October 28th. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will earn $1.67 per share for the year, down from their previous forecast of $1.69. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen’s Q4 2025 earnings at $0.44 EPS and Q2 2026 earnings at $0.51 EPS.

Several other equities analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price target on shares of Repligen in a research note on Wednesday, September 3rd. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the company a “hold” rating in a research report on Tuesday. Evercore ISI raised their target price on shares of Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. Finally, Wells Fargo & Company decreased their price objective on Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $173.85.

Repligen Stock Down 2.6%

NASDAQ:RGEN opened at $144.57 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The company has a market cap of $8.13 billion, a PE ratio of 7,232.12, a PEG ratio of 3.32 and a beta of 1.08. Repligen has a 52-week low of $102.96 and a 52-week high of $182.52. The stock has a 50-day simple moving average of $134.93 and a 200 day simple moving average of $128.74.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. The firm had revenue of $188.80 million during the quarter, compared to analysts’ expectations of $181.23 million. Repligen had a return on equity of 4.70% and a net margin of 0.25%.The company’s revenue was up 21.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS.

Insider Buying and Selling

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of Repligen stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the acquisition, the director owned 1,800 shares of the company’s stock, valued at approximately $201,834. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Institutional investors have recently made changes to their positions in the company. Twin Tree Management LP bought a new stake in Repligen in the 1st quarter valued at $29,000. Hantz Financial Services Inc. boosted its stake in Repligen by 2,663.6% in the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 293 shares during the period. Signaturefd LLC boosted its position in shares of Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 128 shares during the period. CWM LLC boosted its position in shares of Repligen by 67.2% in the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 135 shares during the period. Finally, Center for Financial Planning Inc. boosted its position in shares of Repligen by 34.2% in the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 126 shares during the period. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.